Anxiety News and Research

Latest Anxiety News and Research

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

CAMFT listed in 2010 Associations Advance America Honor Roll

The California Association of Marriage and Family Therapists has been named to the 2010 Associations Advance America Honor Roll, a national awards competition sponsored by the American Society of Association Executives & The Center for Association Leadership, Washington, D.C.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

New data shows Ohio children with special health care needs have inadequate insurance coverage

A third of Ohio children with special health care needs have unstable or inadequate insurance coverage despite the fact that they may qualify for government health programs, according to a new data analysis by the Child Policy Research Center at Cincinnati Children's Hospital Medical Center.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

15 Jun 2010

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.

15 Jun 2010

Retiring health care professionals may strain an overburdened system

The Washington Post: "Since the passage of the health-care law in March, much has been said about the coming swarm of millions of retiring baby boomers and the strain they will put on the nation's health-care system. That's only half the problem. Overlooked in the conversation is a particular group of boomers: doctors and nurses who are itching to call it quits.

15 Jun 2010

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

Apple juice can be a useful supplement for calming the declining moods that are part of the normal progression of moderate-to-severe Alzheimer's Disease, according to a study in American Journal of Alzheimer's Disease and Other Dementias, published by SAGE.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Research may lead to better treatments for depression and substance abuse

In what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to another.

11 Jun 2010

Videoconferencing experience enriches nursing home residents' lives: Study

34 residents from ten nursing homes took part in the videoconferencing study - the 18 women and 16 men had an average age of 75. All of them said the experience enriched their lives, just under two-thirds said it was the second-best option to family visiting and a third said it gave them a true picture of family life. The benefits were considerable and could easily be replicated in a wide range of residential care settings, say the authors.

10 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Traditionally, the most successful methods used to combat stage fright have been prescribed medications (beta blockers) and aerobic exercise. In the most recent issue of Biofeedback, researchers studied another technique: the effect of biofeedback training on Musical Performance Anxiety (MPA). MPA is a severe form of stage fright marked by high anxiety levels and impaired performance.

9 Jun 2010

Research findings hold promise for debilitating emotional symptoms of FXS

The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.

9 Jun 2010

Anxiety News and Research

Latest Anxiety News and Research

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Scientists identify symptoms associated with late-onset hypogonadism

CAMFT listed in 2010 Associations Advance America Honor Roll

Stress-related psychiatric disorders more common among women: Study

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

New data shows Ohio children with special health care needs have inadequate insurance coverage

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

Retiring health care professionals may strain an overburdened system

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Olfactory function tests could help in treating patient in early stages of PD

Chiasma successfully completes Phase I clinical study of Octreolin

Research may lead to better treatments for depression and substance abuse

Videoconferencing experience enriches nursing home residents' lives: Study

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Research findings hold promise for debilitating emotional symptoms of FXS

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Anxiety News and Research

Latest Anxiety News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in